Drug Trial Radar · NCT04054414
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
Last checked: Nov 19, 2026Latest source record: Jul 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jan 10, 2019
Primary completion
Jun 2026
Study completion Jul 2026
Sponsor
- Lead sponsor
- Pharmazz, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in patients of acute spinal cord injury.
Conditions
- Acute Spinal Cord Injury
Interventions
Normal Saline along with standard treatmentDrug
The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
PMZ-1620 along with standard treatmentDrug
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of PMZ-1620 related adverse eventsTime frame: 90 days
- Number of patients not receiving full treatmentTime frame: 90 days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre
Belagavi, India · Not yet recruiting
Institute of Postgraduate Medical Education & Research and SSKM Hospital
Kolkata, India · Recruiting
King George's Medical University
Lucknow, India · Recruiting
Rahate Surgical Hospital & ICU
Nagpur, India · Recruiting
Indian Spinal Injury Centre
New Delhi, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.